Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future

Nick van Es; Cihan Ay; Luis Jara-Palomares

doi:10.1055/a-1150-2286

Hämostaseologie, Table of Contents

Hamostaseologie 2020; 40(03): 270-279
DOI: 10.1055/a-1150-2286

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future

Authors

Nick van Es

¹Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, Amsterdam, The Netherlands
Cihan Ay

²Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Luis Jara-Palomares

³Department of Pneumonology, Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen del Rocío, Seville, Spain

Abstract

A strong link between cancer and thrombosis has been well recognized. The occurrence of venous thromboembolism (VTE) can be the first clinical sign of an undiagnosed (i.e., occult) cancer. Cancer is more often diagnosed after unprovoked compared with provoked VTE events, with a reported risk in recent studies of around 5%. Extensive, imaging-based screening strategies to detect occult cancer after unprovoked VTE do not appear to have a clear clinical benefit compared with a more limited cancer screening. To identify patients with unprovoked VTE at high risk of occult cancer, risk factors have been explored and prediction models developed. Relevant risk factors for occult cancer include male sex, age, anemia, chronic lung disease, and thrombocytosis. Studies with preselection of patients based on risk assessment and evaluation of limited versus extensive screening strategies are currently ongoing. Also, novel and promising approaches for early detection of cancer in patients with unprovoked VTE by means of liquid biopsies, which include analysis of circulating tumor cells, cell-free tumor DNA, proteomics, or platelet mRNA sequencing, are currently under investigation. In this review, we provide an overview of the risk of cancer diagnosis after VTE, discuss the studies which investigated different screening strategies for occult cancer, summarize risk factors and risk scoring models for identification of patients at high risk of cancer diagnosis after VTE, and highlight ongoing research to optimize screening and identification of patients at risk of occult cancer, which will shape the future clinical practice.

Keywords

cancer - venous thromboembolism - thrombosis

Full Text

References

References
1 Rézig S, Mao RL, Couturaud F, Lacut K, Delluc A. Incidence of cancer after a second unprovoked venous thromboembolic event. Thromb Haemost 2019; 119 (03) 490-495
2 Gheshmy A, Carrier M. Venous thromboembolism and occult cancer: impact on clinical practice. Thromb Res 2016; 140 (Suppl. 01) S8-S11
3 Khan F, Rahman A, Carrier M. Occult cancer detection in venous thromboembolism: the past, the present, and the future. Res Pract Thromb Haemost 2017; 1 (01) 9-13
4 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. ; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
5 Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Intern Med 2008; 149 (05) 323-333
6 van Es N, Le Gal G, Otten H-M. , et al. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med 2017; 167 (06) 410-417
7 Marks MA, Engels EA. Venous thromboembolism and cancer risk among elderly adults in the United States. Cancer Epidemiol Biomarkers Prev 2014; 23 (05) 774-783
8 Monreal M, Lensing AWA, Prins MH. , et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2 (06) 876-881
9 Jara-Palomares L, Otero R, Jimenez D. , et al; RIETE Investigators. Development of a risk prediction score for occult cancer in patients with VTE. Chest 2017; 151 (03) 564-571
10 Prandoni P, Lensing AW, Büller HR. , et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327 (16) 1128-1133
11 Schutgens REG, Beckers MMJ, Haas FJLM, Biesma DH. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90 (02) 214-219
12 Galanaud J-P, Arnoult AC, Sevestre M-A. , et al; OPTIMEV-SFMV Investigators. Impact of anatomical location of lower limb venous thrombus on the risk of subsequent cancer. Thromb Haemost 2014; 112 (06) 1129-1136
13 Kraaijpoel N, van Es N, Raskob GE. , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thromb Haemost 2018; 118 (07) 1270-1278
14 Bertoletti L, Robin P, Jara-Palomares L. , et al; MVTEP Investigators. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. J Thromb Haemost 2017; 15 (11) 2184-2187
15 Jara-Palomares L, Otero R, Jimenez D. , et al; RIETE Registry. Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS One 2018; 13 (03) e0194673
16 Gaciong Z, Pruszczyk P, Religa P. Cancer screening in unprovoked venous thromboembolism. N Engl J Med 2015; 373 (25) 2474-2475
17 Bettegowda C, Sausen M, Leary RJ. , et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6 (224) 224ra24
18 Best MG, Sol N, Kooi I. , et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015; 28 (05) 666-676
19 Best MG, Sol N, In 't Veld SGJG. , et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell 2017; 32 (02) 238.e9-252.e9
20 Cohen JD, Li L, Wang Y. , et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; 359 (6378): 926-930
21 Ferreyro BL, Angriman F, Giunta D. , et al. Predictive score for estimating cancer after venous thromboembolism: a cohort study. BMC Cancer 2013; 13: 352
22 Beaber EF, Kim JJ, Schapira MM. , et al; Population-based Research Optimizing Screening through Personalized Regimens Consortium. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst 2015; 107 (06) djv120
23 Piccioli A, Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost 2003; 1 (11) 2271-2272
24 Van Doormaal FF, Terpstra W, Van Der Griend R. , et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted?. J Thromb Haemost 2011; 9 (01) 79-84
25 Carrier M, Lazo-Langner A, Shivakumar S. , et al; SOME Investigators. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med 2015; 373 (08) 697-704
26 Robin P, Le Roux P-Y, Planquette B. , et al; MVTEP Study Group. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol 2016; 17 (02) 193-199
27 Robin P, Otten HM, Delluc A. , et al. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thromb Res 2018; 171 (August): 92-96
28 Robertson L, Yeoh SE, Broderick C, Stansby G, Agarwal R. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev 2018; 11 (11) CD010837
29 Robin P, Le Roux PY, Tromeur C. , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res 2017; 159 (September): 48-51
30 Ihaddadene R, Corsi DJ, Lazo-Langner A. , et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood 2016; 127 (16) 2035-2037
31 Rosell A, Lundström S, Mackman N, Wallén H, Thålin C. A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism. J Thromb Thrombolysis 2019; 48 (01) 111-118
32 Han D, , ó Hartaigh B, Lee JH. , et al. Impact of D-dimer for prediction of incident occult cancer in patients with unprovoked venous thromboembolism. PLoS One 2016; 11 (04) e0153514